Tumorigenesis and attendant safety risks are significant concerns of induced pluripotent stem cell (iPSC)-based therapies. Thus, it is crucial to evaluate iPSC proliferation, differentiation, and tumor formation after transplantation. Several approaches have been employed for tracking the donor cells, including fluorescent protein and luciferase, but both have limitations. Here, we introduce a protocol using iRFP genetic labeling technology to track tumor formation of iPSCs in skeletal muscle after CRISPR/Cas9 gene editing.
CITATION STYLE
Jin, Y., Shen, Y., Weintraub, N. L., & Tang, Y. (2020). Using iRFP Genetic Labeling Technology to Track Tumorogenesis of Transplanted CRISPR/Cas9-Edited iPSC in Skeletal Muscle. In Methods in Molecular Biology (Vol. 2126, pp. 73–83). Humana Press Inc. https://doi.org/10.1007/978-1-0716-0364-2_7
Mendeley helps you to discover research relevant for your work.